



Dedicated To Life

March 7, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Zydus receives Post Application Action Letter for the USFDA cGMP nd Pre-Approval Inspection (PAI) at the Ahmedabad API facility *This confirms that the inspected facility has been considered as ready to commercially manufacture and supply the Enzalutamide API.*

Dear Sir / Madam,

We wish to inform that the company has received Post Application Action Letter from the USFDA for the inspection conducted at the Ahmedabad API facility of Zydus Lifesciences Limited, confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. This facility underwent for-cause cGMP surveillance and Pre-Approval Inspection for manufacturing of drug substances Enzalutamide from 14th to 22nd Dec 2023.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI

COMPANY SECRETARY

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

